Azupedia

Novo Nordisk: Difference between revisions

Newer edit →
VisualWikitext
Created page with "{{Short description|Danish pharmaceutical company}} {{Infobox company | name = Novo Nordisk A/S | logo = Novo Nordisk - Logo.svg | logo_caption= The Novo Nordisk logo, a bull with a sun disk between his horns, is based on the Egyptian deity Apis. | image = Novo Nordisk headquarters building Denmark.jpg | image_caption = Headquarters in Bagsværd, Denmark | type = Public | traded_as = {{ubl|class=nowrap|{{OMX|CSE1158|NOVO B}}|OMX Copenhagen 25..."
 
No edit summary
Line 2: Line 2:
{{Infobox company
{{Infobox company
| name = Novo Nordisk A/S
| name = Novo Nordisk A/S
| logo = Novo Nordisk - Logo.svg
| logo = <!-- Novo Nordisk - Logo.svg -->
| logo_caption= The Novo Nordisk logo, a bull with a sun disk between his horns, is based on the Egyptian deity Apis.  
| logo_caption= <!--The Novo Nordisk logo, a bull with a sun disk between his horns, is based on the Egyptian deity Apis. -->
| image = Novo Nordisk headquarters building Denmark.jpg
| image = Novo Nordisk headquarters building Denmark.jpg
| image_caption = Headquarters in [[Bagsværd]], Denmark
| image_caption = Headquarters in [[Wikipedia:Bagsværd|Bagsværd]], {{Country|デンマーク}}
| type = [[Public company|Public]]
| type = [[:en:Public company|Public]]
| traded_as = {{ubl|class=nowrap|{{OMX|CSE1158|NOVO B}}|[[OMX Copenhagen 25]] component|{{nyse|NVO}}}}
| traded_as = {{ubl|class=nowrap|{{OMX|CSE1158|NOVO B}}|[[OMX Copenhagen 25]] component|{{nyse|NVO}}}}
| key_people = {{ubl|[[Helge Lund]] ([[Chairman]])|[[Lars Fruergaard Jørgensen]] (president and [[CEO]])}}
| key_people = {{ubl|[[Wikipedia:Helge Lund|Helge Lund]] ([[Wikipedia:Chairman|Chairman]])|[[Wikipedia:Lars Fruergaard Jørgensen|Lars Fruergaard Jørgensen]] (president and [[Wikipedia:CEO|CEO]])}}
| industry = [[Pharmaceuticals]], [[Health care]]
| industry = [[Pharmaceuticals/ja]], [[Health care/ja]]
| products = {{Hlist|[[Ozempic]]| [[Ryzodeg]]| [[Victoza]]| [[NovoEight]]| [[Activella]]| Novolin<!--intentional link to DAB page-->| [[Levemir]]| [[NovoSeven]]| [[Norditropin]]| [[Tresiba]]| [[Xultophy]]| [[NovoRapid]]| [[Fiasp]]| [[Saxenda]]}}
| products = {{Hlist|[[Ozempic/ja]]| [[Ryzodeg/ja]]| [[Victoza/ja]]| [[NovoEight/ja]]| [[Activella/ja]]| Novolin<!--intentional link to DAB page-->| [[Levemir/ja]]| [[NovoSeven/ja]]| [[Norditropin/ja]]| [[Tresiba/ja]]| [[Xultophy/ja]]| [[NovoRapid/ja]]| [[Fiasp/ja]]| [[Saxenda/ja]]}}
| revenue = {{Increase}} {{DKK|232.3 billion|link=yes}} (2023)
| revenue = {{Increase}} {{DKK|232.3 billion|link=yes}} (2023)
| operating_income = {{Increase}} {{DKK|102.6 billion}} (2023)
| operating_income = {{Increase}} {{DKK|102.6 billion}} (2023)
Line 20: Line 20:
| foundation = {{start date and age|df=yes|1923|12|21}}
| foundation = {{start date and age|df=yes|1923|12|21}}
| hq_location =  
| hq_location =  
| hq_location_city = [[Bagsværd]]
| hq_location_city = [[Wikipedia:Bagsværd|Bagsværd]]
| hq_location_country = [[Denmark]]
| hq_location_country = [[Wikipedia:Denmark|Denmark]]
| owner = [[Novo Holdings A/S]] (28%)
| owner = [[Wikipedia:Novo Holdings A/S|Novo Holdings A/S]] (28%)
| footnotes =
| footnotes =
}}
}}
[[File:Novo Nordisk - Logo 2.svg|thumb|200px|Former logo]]
[[File:Novo Nordisk - Logo 2.svg|thumb|200px|Former logo]]


'''Novo Nordisk A/S''' is a [[Denmark|Danish]] multinational [[pharmaceutical company]] headquartered in [[Bagsværd]] with production facilities in nine countries and affiliates or offices in five countries. Novo Nordisk is controlled by majority shareholder [[Novo Holdings A/S]] which holds approximately 28% of its shares and a [[majority]] (77%) of its voting shares.
'''Novo Nordisk A/S'''は、[[:en:Danish|デンマーク]]の多国籍[[pharmaceutical company/ja|製薬会社]]で、[[:en:Bagsværd|バッグスベアード]]に本社を置き、9カ国に生産拠点、5カ国に関連会社または事務所を持つ。Novo Nordiskは大株主である[[Wikipedia:Novo Holdings A/S|Novo Holdings A/S]]によって支配されており、同社は株式の約28%、議決権株式の[[:ja:過半数|過半数]]（77%）を保有している。


Novo Nordisk manufactures and markets [[pharmaceutical]] products and services, specifically [[diabetes]] care medications and devices. Its main product is the drug [[semaglutide]], used to treat diabetes under the brand name Ozempic and obesity under the brand name Wegovy. Novo Nordisk is also involved with [[hemostasis]] management, [[growth hormone]] therapy, and [[Hormone replacement therapy (menopause)|hormone replacement therapy]]. The company makes several drugs under various brand names, including [[Levemir]], [[Tresiba]], [[NovoLog]], Novolin R, [[NovoSeven]], [[NovoEight]], and [[Victoza]].
Novo Nordiskは[[pharmaceutical/ja|医薬品]]製品およびサービス、特に[[diabetes/ja|糖尿病]]治療医薬品および機器を製造・販売している。主な製品は[[semaglutide/ja|セマグルチド]]という薬物で、オゼンピックという商品名で糖尿病の治療に、ウゴービという商品名で肥満症の治療に使用されている。Novo Nordiskはまた、[[hemostasis/ja|止血]]管理、[[growth hormone/ja|成長ホルモン]]療法、[[Hormone replacement therapy (menopause)/ja|ホルモン補充療法]]にも携わっている。同社は、[[levemir/ja|レベミル]]、[[tresiba/ja|トレシーバ]]、[[NovoLog/ja|ノボログ]]、ノボリンR、[[NovoSeven/ja|ノボセブン]]、[[NovoEight/ja|ノボエイト]]、[[Victoza/ja|ビクトーザ]]など、さまざまなブランド名で複数の薬物を製造している。


Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies which date back to the 1920s. The Novo Nordisk logo is the [[Apis bull]], one of the sacred animals of [[ancient Egypt]]. Novo Nordisk is a full member of the [[European Federation of Pharmaceutical Industries and Associations]] (EFPIA).
Novo Nordiskは全世界で48,000人以上の従業員を擁し、168カ国で製品を販売している。Novo Nordiskは1989年、1920年代にさかのぼるデンマークの2社が合併して誕生した。Novo Nordiskのロゴは、[[:en:ancient Egypt|古代エジプト]]の神聖な動物のひとつである[[:en:Apis bull|アピス牛]]である。Novo Nordiskは[[:en:European Federation of Pharmaceutical Industries and Associations|欧州製薬団体連合会]]（EFPIA）の正会員である。


The company was ranked 25th among the [[100 Best Companies to Work For]] in 2010 and 72nd in 2014 by ''[[Fortune (magazine)|Fortune]]''. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine ''[[Corporate Knights]],'' while spin-off company [[Novozymes]] was named fourth. Novo Nordisk is the largest pharmaceutical company in Denmark. Novo Nordisk's [[market capitalization]] exceeded the GDP of Denmark's [[economy of Denmark|domestic economy]] in 2023, and it is the highest valued pharmaceutical company in Europe.
''[[Fortune (magazine)|フォーチュン誌]]''では2010年に25位、2014年には72位にランクインしている。2012年1月、Novo Nordiskはビジネス誌''[[:en:Corporate Knights|コーポレート・ナイツ]]''によって世界で最も持続可能な企業に選ばれ、スピンオフ企業である[[:en:Novozymes|ノボザイムズ]]は4位に選ばれた。Novo Nordiskはデンマーク最大の製薬会社である。Novo Nordiskの[[:en:market capitalization|時価総額]]は、2023年には[[:en:economy of Denmark|デンマークの経済]]GDPを超え、ヨーロッパで最も高い評価を受けている製薬会社である。
 
__TOC__


==History==
==History==
Retrieved from "https://wiki.tiffa.net/wiki/Novo_Nordisk"